Abstract P6-07-41: Sub classification of early stage hormone positive (HP) Her-2 negative breast cancer (BC) by immunohistochemistry (IHC) into intrinsic subtypes (IS) and their correlation with Oncotype Recurrence Score (RS)

AbstractMulti-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with oestrogen-receptor-positive (ER+), HER2-negative breast cancer. Here, we describe the development and validation of methods to recapitulate RS, EP and ROR scores from NanoString expression data. RNA was available from 107 tumours from postmenopausal women with early-stage, ER+, HER2− breast cancer from the translational Arimidex, Tamoxifen, Alone or in Combination study (TransATAC) where previously these signatures had been assessed with commercial methodology. Gene expression was measured using NanoString nCounter. For RS and EP, conversion factors to adjust for cross-platform variation were estimated using linear regression. For ROR, the steps to perform subgroup-specific normalisation of the gene expression data and calibration factors to calculate the 46-gene ROR score were assessed and verified. Training with bootstrapping (n = 59) was followed by validation (n = 48) using adjusted, research use only (RUO) NanoString-based algorithms. In the validation set, there was excellent concordance between the RUO scores and their commercial counterparts (rc(RS) = 0.96, 95% CI 0.93–0.97 with level of agreement (LoA) of −7.69 to 8.12; rc(EP) = 0.97, 95% CI 0.96–0.98 with LoA of −0.64 to 1.26 and rc(ROR) = 0.97 (95% CI 0.94–0.98) with LoA of −8.65 to 10.54). There was also a strong agreement in risk stratification: (RS: κ = 0.86, p < 0.0001; EP: κ = 0.87, p < 0.0001; ROR: κ = 0.92, p < 0.001). In conclusion, the calibrated algorithms recapitulate the commercial RS and EP scores on individual biopsies and ROR scores on samples based on subgroup-centreing method using NanoString expression data.

Download Full-text

Is the 21-Gene Recurrence Score on Core Needle Biopsy Equivalent to Surgical Specimen in Early-Stage Breast Cancer? A Comparison of Gene Expression Between Paired Core Needle Biopsy and Surgical Specimens

Annals of Surgical Oncology ◽

10.1245/s10434-021-10457-5 ◽

2021 ◽

Author(s):

Javier I. J. Orozco ◽

Shu-Ching Chang ◽

Chikako Matsuba ◽

Miquel Ensenyat-Mendez ◽

Gary L. Grunkemeier ◽

...

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

Core Needle Biopsy ◽

Needle Biopsy ◽

Early Stage ◽

Recurrence Score ◽

Early Stage Breast Cancer ◽

Surgical Specimen ◽

Core Needle

Download Full-text

Application of RSClin to guide treatment recommendations for premenopausal patients with early-stage hormone-positive breast cancer and intermediate risk oncotype recurrence scores.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e12511 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e12511-e12511

Author(s):

Brittney Shulman Zimmerman ◽

Shana Berwick ◽

Alaina J Kessler ◽

Danielle Seidman ◽

Sara Malin Hovstadius ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Medical Center ◽

Academic Medical Center ◽

Recurrence Score ◽

Treatment Recommendations ◽

Definitive Treatment ◽

Treatment Recommendation ◽

Intermediate Risk ◽

Premenopausal Patients

e12511 Background: The RSClin model, which incorporates the Oncotype Recurrence Score (RS) and clinicopathologic features, was recently developed to further tailor prognosis and prediction of chemotherapy benefit for patients with early-stage hormone positive (HR+) breast cancer (BC) (Sparano et al, 2020). The RSClin calculator is available online to assist treatment planning for situations where chemotherapy benefit is uncertain. Covariates include Oncotype RS, tumor grade, tumor size and patient age. The risk calculator generates a 10-year distant recurrence risk and absolute chemotherapy benefit. This tool may be especially helpful to determine treatment management for premenopausal patients with early-stage HR+ BC with intermediate risk (IR) Oncotype RS (16-25). We retrospectively applied RSClin to this patient population to determine if it would have changed treatment recommendations. Methods: We identified premenopausal women with node-negative early-stage BC with IR RS (16-25) within our large Oncotype database. Using the RSClin model, we selected >5% absolute chemotherapy benefit as a reasonable cutoff to recommend chemotherapy. We compared the treatment recommendation based on RSClin with the treatment previously recommended by breast oncologists at our large academic medical center in New York City. Results: There were 86 patients who met criteria with a median age of 46 years. Of these, 26 patients (30%) were recommended chemotherapy plus endocrine therapy (ET) and 60 (70%) were recommended ET alone. After applying the RSClin model (data available for 83/86 patients), 19 (23%) would have resulted in a change in treatment recommendation and 64 (77%) would have remained unchanged. Overall, 8 (10%) would have withheld chemotherapy when it was previously offered and 11 (13%) would have recommended chemotherapy when it was previously excluded. There were 8 (9%) secondary invasive breast events in this population, with 2 (2%) being ipsilateral, 3 (3%) being contralateral and 3 (3%) metastatic at a median follow up of 46.9 months. Conclusions: The RSClin model would have changed management of premenopausal patients with IR RS in 23% of patients. This model, although not yet prospectively validated, may help individualize therapy for patients with less definitive treatment plans. Using RSClin, we can aim to minimize recurrence rates and avoid unnecessary chemotherapy in selected patients. This model is easy to apply and will have important clinical utility moving forward.

Download Full-text

Molecular classification of breast cancer. Treatment and prognosis implications.

Cirugía Andaluza ◽

10.37351/2021322.9 ◽

2021 ◽

Vol 32 (2) ◽

pp. 155-159

Author(s):

M Alcaide Lucena ◽

CJ Rodríguez González ◽

S de Reyes Lartategui ◽

R Gallart Aragón ◽

MT Sánchez Barrón ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Treatment ◽

Molecular Classification ◽

Breast Cancer Treatment ◽

Cáncer De Mama ◽

Luminal A ◽

Luminal B ◽

Her 2

Resumen Los avances recientes en el campo de la biología molecular y la secuenciación del genoma se han traducido en una nueva clasificación del cáncer de mama, que busca mayor precisión y se correlaciona mejor con el riesgo de recaída de la enfermedad y la respuesta al tratamiento. Establece cuatro subtipos de cáncer de mama: luminal A, luminal B, HER 2 positivo y triple negativo, siendo el subtipo luminal A el de mejor pronóstico, y el triple negativo, el de peor pronóstico. Si combinamos la clasificación clásica histológica con la nueva molecular, nos permite encuadrar a estas pacientes de una forma más precisa en función del riesgo, definiendo así un manejo terapéutico adaptado.

Download Full-text

Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer

Drugs for HER-2-positive Breast Cancer ◽

10.1007/978-3-0346-0094-1_2 ◽

2010 ◽

pp. 33-49

Author(s):

Rupert Bartsch ◽

Guenther G. Steger

Keyword(s):

Breast Cancer ◽

Adjuvant Treatment ◽

Early Stage ◽

Her 2 ◽

Positive Breast Cancer

Download Full-text

P253 Economic impact of 21-gene recurrence score testing on early stage breast cancer in Ireland

The Breast ◽

10.1016/s0960-9776(15)70285-7 ◽

2015 ◽

Vol 24 ◽

pp. S113 ◽

Cited By ~ 2

Author(s):

L. Smyth ◽

G. Watson ◽

C.M. Kelly ◽

M. Keane ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Economic Impact ◽

Early Stage ◽

Recurrence Score ◽

Early Stage Breast Cancer

Download Full-text

Application of green synthesized WO3-poly glutamic acid nanobiocomposite for early stage biosensing of breast cancer using electrochemical approach

Scientific Reports ◽

10.1038/s41598-021-03209-8 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Hassan Nasrollahpour ◽

Abdolhossein Naseri ◽

Mohammad-Reza Rashidi ◽

Balal Khalilzadeh

Keyword(s):

Breast Cancer ◽

Glutamic Acid ◽

Electrochemical Biosensor ◽

Early Stage ◽

Clinical Samples ◽

Breast Cancer Patients ◽

Serum Samples ◽

Electrochemical Approach ◽

Her 2

AbstractBiopolymer films have drawn growing demand for their application in the point of care domain owing to their biocompatibility, eco-friendly, and eligibility for in vivo analyses. However, their poor conductivity restricts their sensitivity in diagnostics. For high-quality electrochemical biosensor monitoring, two vital factors to be greatly paid attention are the effective merge of amplification modifiers with transducing surface and the superior linking across the recognition interface. Here, we introduce an enzyme-free electrochemical biosensor based on electrosynthesized biocompatible WO3/poly glutamic acid nano-biocomposites to address the hardships specific to the analysis of circulating proteins clinical samples. In addition to its green synthesis route, the poor tendency of both components of the prepared nano-biocomposite to amine groups makes it excellent working in untreated biological samples with high contents of proteins. Several electrochemical and morphological investigations (SEM, EDX, and dot mapping) were fulfilled to gain a reliable and trustful standpoint of the framework. By using this nanobiosensor, the concentration of HER-2 was detectable as low as 1 fg mL−1 with a wide linear response between 1 ng mL−1 and 1 fg mL−1. Meanwhile, the protocol depicted ideal specificity, stability, and reproducibility for the detection of HER-2 protein in untreated serum samples of breast cancer patients.

Download Full-text